FDA Approves New Imaging System to Enhance Cervical Cancer Detection
BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System.
BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
Articles in this issue
The Absent-Minded Professor: An Unusual Complication of Melanoma
Inflammatory Breast Cancer: A Complex Disease
Defining the IBC Phenotype
Acupuncture
Two Orphan Drug Designations Granted for Reviroc in NHL
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancer
FDA Considers Update for Tanning Bed Labels
FDA Approves New Imaging System to Enhance Cervical Cancer Detection
Fostamatinib Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia
Dexamethasone in Induction Can Eliminate One-Third of All Relapses in Childhood Acute Lymphoblastic Leukemia
Novel Antifolate Pralatrexate Shows Promise in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Alemtuzumab May Lead to Longer Overall Survival in CLL Patients With Poor Prognostic Factors
21st Century Challenge of Ovarian Cancer in the Elderly
Molecular Determinants of the Inflammatory Breast Cancer Phenotype
Recent Videos
Related Content
